Mapping Pathways Reveals Importance of Localised Strategies for Using ARVs to Prevent HIV/AIDS
Feb 10, 2014
This is the first international report on HIV prevention with antiretroviral (ARV) drugs that brings scientific evidence together with community perspectives. We show that ARV-based prevention needs to be tailored to local contexts and cultures.
Developing evidence-based, people-centred strategies for the use of antiretrovirals as prevention
|PDF file||6.3 MB|
|PDF file||0.1 MB|
Mapping Pathways is a multinational project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral (ARV)-based prevention strategies to end the HIV/AIDS epidemic. The project is based on the premise that the current array of prevention options is not sufficient; new pathways to prevention, based on enhanced assessment and analysis of likely impact, are needed to address new infections adequately.
ARVs are opening up new options for HIV prevention, such as 'treatment as prevention' (often referred to as 'TLC+' [testing, linkage to care], plus treatment), microbicides, oral pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). There are multifaceted challenges associated with these new prevention strategies related to access, cost, behavioural and health impacts, and implementation.
Mapping Pathways: Developing evidence-based, people-centred strategies for the use of antiretrovirals as prevention is designed to support critical thinking and development of a new research agenda for the analysis of multiple policy options — the pathways — that should be considered by prevention planners, programmers and funders when addressing the opportunities and challenges of the new ARV paradigm.
The Mapping Pathways journey: snapshots from the beginning
Snapshots from the empirical literature
Snapshots from the grassroots evidence base
Snapshots from the grasstops evidence base
Snapshots from the ExpertLens survey
An integrated perspective: how to map pathways to good decisionmaking
The research described in this report was sponsored by Merck & Co. and conducted by RAND Europe.
This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.